NEW YORK, and PETACH TIKVAH, Israel, Jan. 6, 2015 /TRENDINGGLOBALNEWS/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Tony Fiorino, MD, PhD, Chief Executive Officer, will be presenting at two upcoming investor conferences.
- On Wednesday January 14 at 4:30 PM PST (7:30 PM EST), Dr. Fiorino will be presenting at the Biotech Showcase™ 2015 Conference in San Francisco, CA. A webcast of the conference will be available at: http://edge.media-server.com/m/p/gvhaff2q.
- On Monday, January 19 at 4:30 PM EST, Dr. Fiorino will be presenting at the Noble Financial Capital Markets Equity Conference in Port St. Lucie, FL. A webcast of the conference will be available through the Noble Financial website at: http://noble.mediasite.com/mediasite/Play/bbe3ecedd7f849dcb604c6a7ef5718531d.
We
recommend investors register for webcasts at least 10 minutes prior to
the scheduled start of the presentation to ensure timely access. These
links can also be found on BrainStorm Cell Therapeutics website, www.brainstorm-cell.com.
About BrainStorm Cell Therapeutics Inc.BrainStorm
Cell Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived from
autologous bone marrow cells for the treatment of neurodegenerative
diseases. The Company holds the rights to develop and commercialize its
NurOwn™ technology through an exclusive, worldwide licensing agreement
with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement –
Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s
actual results to differ materially from those stated or implied by such
forward-looking statements. Terms and phrases such as "may", "should",
"would", "could", "will", "expect", "likely", "believe", "plan",
"estimate", "predict", "potential", and similar terms and phrases are
intended to identify these forward-looking statements. The potential
risks and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain required
regulatory approvals; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These
factors should be considered carefully, and readers should not place
undue reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are based on
the beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions if
circumstances or management's beliefs, expectations or opinions should
change, unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, levels of activity, performance or
achievements.
source:http://www.prnewswire.com/
0 comments:
Post a Comment